Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication

19 Oct 2023
www.fiercepharma.com
Phase 3Cell TherapyClinical ResultPhase 2Drug Approval
Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication
Preview
Source: FiercePharma
Takeda said it will “assess the financial impacts of the study results," after Alofisel came up short in a phase 3 trial.
After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication.
Alofisel (daradstrocel), a stem cell therapy designed to treat one of the most debilitating complications of Crohn’s—complex perianal fistulas (CPF)—has come up short in a phase 3 trial.
In the 569-patient ADMIRE-CD II study, Alofisel did not meet its primary endpoint of combined remission at 24 weeks. Takeda did not report the full data, saving the reveal for a future medical meeting or a peer-reviewed journal, the Japan-based company said.
“While we are disappointed with this outcome, we recognize that medical research for difficult-to-treat conditions such as complex CPF remains challenging,” Chinwe Ukomadu, Takeda’s head of the GI & inflammation therapeutic area unit, said in a release. “We believe there are valuable lessons to learn from ADMIRE-CD II.”
Takeda did not reveal its plan for Alofisel as it continues to “assess the financial impacts of the study results, including impairment loss for intangible assets,” the company said. Any potential revisions to the company's forecast for the fiscal year will be announced during its second-quarter earnings call on Oct. 26.
Around 1 in 3 Crohn's patients develop a fistula, or a narrow tunnel that connects an organ to another part of the body. For patients with CPF, the fistulas form near the anus.
Alofisel is approved in the U.K. and the European Union for patients with CPF who haven’t responded to previous therapy. The nods were based on results from the 212-patient ADMIRE-CD study, which showed remission rates of 51.5% for treated patients versus 35.6% for the control group after 24 weeks.
Alofisel also was endorsed in Takeda's’ home country, supported by positive data from the Darvadstrocel-3002 trial, which was conducted in Japan.
Earlier this year, Takeda grounded Crohn's prospect sibofimloc, an FimH blocker, which was previously set for a phase 2 trial before it was terminated because of a lack of enrollees.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.